These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 15327804

  • 1. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen.
    Ta LE, Dionne RA.
    Pain; 2004 Sep; 111(1-2):13-21. PubMed ID: 15327804
    [Abstract] [Full Text] [Related]

  • 2. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
    Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS.
    Mayo Clin Proc; 1999 Nov; 74(11):1095-105. PubMed ID: 10560596
    [Abstract] [Full Text] [Related]

  • 3. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S, Robbins J, West CR, Nemeth MA.
    Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
    [Abstract] [Full Text] [Related]

  • 4. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.
    J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
    [Abstract] [Full Text] [Related]

  • 5. Celecoxib effectively treats patients with acute shoulder tendinitis/bursitis.
    Petri M, Hufman SL, Waser G, Cui H, Snabes MC, Verburg KM.
    J Rheumatol; 2004 Aug; 31(8):1614-20. PubMed ID: 15290743
    [Abstract] [Full Text] [Related]

  • 6. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS.
    Scand J Rheumatol Suppl; 1999 Aug; 109():31-7. PubMed ID: 10422544
    [Abstract] [Full Text] [Related]

  • 7. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [Abstract] [Full Text] [Related]

  • 8. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
    Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K.
    Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
    Gibofsky A, Rodrigues J, Fiechtner J, Berger M, Pan S.
    Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
    Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, Regourd E, May M.
    Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
    Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS.
    JAMA; 1999 Nov 24; 282(20):1921-8. PubMed ID: 10580457
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS.
    J Rheumatol Suppl; 1999 Apr 24; 56():31-6. PubMed ID: 10225538
    [Abstract] [Full Text] [Related]

  • 17. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis.
    Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S.
    J Rheumatol; 2006 Sep 24; 33(9):1805-12. PubMed ID: 16960941
    [Abstract] [Full Text] [Related]

  • 18. Celecoxib, a COX-2--specific inhibitor: the clinical data.
    Fort J.
    Am J Orthop (Belle Mead NJ); 1999 Mar 24; 28(3 Suppl):13-8. PubMed ID: 10193998
    [Abstract] [Full Text] [Related]

  • 19. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis.
    Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR.
    Semin Arthritis Rheum; 2007 Dec 24; 37(3):164-73. PubMed ID: 17570469
    [Abstract] [Full Text] [Related]

  • 20. Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience.
    Bensen WG.
    J Rheumatol Suppl; 2000 Oct 24; 60():17-24. PubMed ID: 11032098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.